Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.78 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.78 |
| ▸ | DRD3 | P35462 | 3/20 | 0.78 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.78 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.78 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.78 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.78 |
| ▸ | HRH2 | P25021 | 2/20 | 0.78 |
| ▸ | HTR2A | P28223 | 2/20 | 0.78 |
| ▸ | HTR2C | P28335 | 2/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.78 |
| ▸ | HRH1 | P35367 | 2/20 | 0.78 |
| ▸ | HTR2B | P41595 | 2/20 | 0.78 |
| ▸ | HTR6 | P50406 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orphenadrine SCHEMBL119471 | 0.88 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| Orphenadrine SCHEMBL29359844 | 0.88 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| Orphenadrine SCHEMBL28727 | 0.88 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| Orphenadrine SCHEMBL30903909 | 0.87 | LMNA (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| Orphenadrine SCHEMBL1235378 | 0.87 | LMNA (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| SCHEMBL16349409 | 0.86 | SLC6A2 (0.73) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| Orphenadrine SCHEMBL4338150 | 0.85 | SLC6A2 (0.94) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| SCHEMBL4667597 | 0.84 | CYP2D6 (0.76) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| SCHEMBL15529408 | 0.84 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| SCHEMBL7688529 | 0.82 | CYP2D6 (0.74) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12310922-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| WO-2001007009-A1 | LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001006829-A2 | LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1054998-A1 | TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE | Pericor Science, Inc. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000053231-A2 | FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF | PROTARGA, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-1999036570-A2 | TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE INC (US) | 1999-07-22 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | SLC6A2 644/4885SLC6A4 642/4885SLC6A3 916/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | SLC6A2 286/4885SLC6A4 120/4885SLC6A3 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.